HC Wainwright Reiterates “Buy” Rating for Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics (NASDAQ:DFTX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $70.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 72.41% from the stock’s current price.

Several other research analysts have also recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of Definium Therapeutics in a report on Monday. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Wall Street Zen downgraded shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Robert W. Baird boosted their target price on shares of Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Finally, Maxim Group set a $55.00 price target on Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $63.00.

Definium Therapeutics Stock Up 4.4%

NASDAQ DFTX traded up $1.71 during mid-day trading on Monday, reaching $40.60. The stock had a trading volume of 2,867,272 shares, compared to its average volume of 2,226,701. The stock has a market cap of $5.46 billion, a PE ratio of -11.84 and a beta of 2.23. Definium Therapeutics has a 1 year low of $8.77 and a 1 year high of $49.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The company has a fifty day moving average price of $43.01 and a 200 day moving average price of $30.33.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, research analysts expect that Definium Therapeutics will post -3.02 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at $9,433,199.61. The trade was a 1.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 67,119 shares of company stock worth $2,887,496. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in Definium Therapeutics during the second quarter valued at approximately $283,999,000. Avoro Capital Advisors LLC purchased a new stake in shares of Definium Therapeutics in the fourth quarter worth $66,950,000. Commodore Capital LP raised its position in shares of Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares during the period. Wellington Management Group LLP bought a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $138,755,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Definium Therapeutics by 8,513.2% during the 4th quarter. Janus Henderson Group PLC now owns 2,411,696 shares of the company’s stock valued at $32,256,000 after buying an additional 2,383,696 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its second Phase 3 study of DT120 ODT met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with GAD. The successful result follows positive findings from an earlier late-stage study, providing additional support for the drug’s potential efficacy. Definium’s LSD-based drug lowers anxiety in second successful late-stage study
• Positive Sentiment: The company’s Panorama Phase 3 trial achieved its goal, with topline data indicating meaningful anxiety improvement. Investors are likely viewing the readout as an important step toward a potential regulatory submission for DT120 ODT. Definium Therapeutics Announces Positive Topline Results
• Positive Sentiment: Needham reaffirmed its Buy rating and set a $66 price target, while Royal Bank of Canada previously assigned an Outperform rating. The bullish analyst views add support to the positive market reaction. Definium Therapeutics Earns Outperform Rating
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, reflecting heightened volatility around the Phase 3 disclosure. The company also scheduled a webcast to discuss the results. Definium to Discuss Topline Results
• Neutral Sentiment: Definium granted options covering 56,650 shares to three new employees. The grants may create limited future dilution but are primarily intended as hiring incentives. Definium Announces New Employee Inducement Grants

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.